Study of Lenalidomide (Revlimid) in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL) Patients

Inclusion Criteria: * Patients with histologic diagnosis of PTCL according to the WHO-REAL classification; * Age \> 18 years; * Relapsed (³1) or refractory to conventional chemotherapy/radiotherapy; * Stage I-IV according to the Ann Arbor staging System; * Performance status \<2; * Adequate bone marrow reserve: platelets \>50 x 10(9)/L, absolute neutrophil count * (ANC) \> 1.0 x 10(9)/L, hemoglobin \>8 g/d; * Normal renal and hepatic functions; * Negative HIV, HCV, and HBV status; * Informed consent prior to registration on study Exclusion Criteria: * Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form. * Pregnant or breast feeding females. (Lactating females must agree not to breast feed while taking lenalidomide). * Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study. * Use of any other experimental drug or therapy within 28 days of baseline. * Known hypersensitivity to thalidomide. * The development of erythema if characterized by a desquamating rash while taking thalidomide or similar drugs. * Any prior use of lenalidomide. * Concurrent use of other anti-cancer agents or treatments. * Known positive for HIV or infectious hepatitis, type A, B or C.